title: Renal effects of carprofen and etodolac in euvolemic and volume-depleted dogs.
abstract: OBJECTIVE
  To determine the effects of carprofen and etodolac on renal function in euvolemic dogs and dogs with extracellular fluid volume depletion induced via administration of furosemide.
  
  
  METHODS
  12 female Beagles.
  
  
  METHODS
  Dogs received a placebo, furosemide, carprofen, etodolac, furosemide and carprofen, and furosemide and etodolac. The order in which dogs received treatments was determined via a randomization procedure. Values of urine specific gravity, various plasma biochemical variables, glomerular filtration rate (GFR [urinary clearance of creatinine]), and renal plasma flow (urinary clearance of para-aminohippuric acid) were determined before and after 8 days of drug administration. A washout time of approximately 12 days was allowed between treatment periods.
  
  
  RESULTS
  Administration of furosemide, furosemide and carprofen, and furosemide and etodolac caused changes in urine specific gravity and values of plasma biochemical variables. Administration of carprofen or etodolac alone did not have a significant effect on renal plasma flow or GFR. Concurrent administration of furosemide and carprofen or furosemide and etodolac caused a significant decrease in GFR. After 12-day washout periods, mean values of GFR were similar to values before drug administration for all treatments.
  
  
  CONCLUSIONS
  Results indicated GFR decreased after 8 days of concurrent administration of furosemide and carprofen or furosemide and etodolac to dogs. Administration of preferential cyclooxygenase-2 inhibitors to dogs with extracellular fluid volume depletion or to dogs treated with diuretics may transiently impair renal function.
authors.affiliation: Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
authors.forename: Kathryn K
authors.initials: KK
authors.lastname: Surdyk
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Sloan
authors.forename: Scott A
authors.initials: SA
authors.lastname: Brown
mesh_terms: D000818:Animals; D002227:Carbazoles / Q000494:pharmacology*; D018592:Cross-Over Studies; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004232:Diuretics / Q000494:pharmacology; D004285:Dogs / Q000502:physiology*; D017308:Etodolac / Q000494:pharmacology*; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology / Q000662:veterinary; D020896:Hypovolemia / Q000503:physiopathology / Q000662:veterinary*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D011897:Random Allocation; D010130:p-Aminohippuric Acid / Q000652:urine
chemical_list: D002227:Carbazoles; D052246:Cyclooxygenase 2 Inhibitors; D004232:Diuretics; D017308:Etodolac; D005665:Furosemide; C007005:carprofen; D010130:p-Aminohippuric Acid